Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate


Tuesday, January 13, 2015

Don’t look for pricey hepatitis drugs to come down

More competitors in the market doesn’t equate to lower prices 

SAN FRANCISCO (MarketWatch) — If you’re looking for drug makers to start discounting those pricey, $1,000-a-pill remedies for hepatitis C soon, prepare to be disappointed.

Biopharmaceutical companies like Gilead Sciences Inc. aren’t showing any signs of easing up on the drug prices that have incurred the wrath of insurers and others in the health-care arena, who claim the makers of hepatitis C remedies are gouging the public. It also doesn’t appear that more competitors expected to come to market with their own hepatitis C medications are overly concerned they’ll have trouble selling the drugs.

From what the drug makers are saying, cutting the price is not their highest priority.

Read more...
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)